These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 6814139)

  • 1. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
    Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
    Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
    Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
    Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estradiol plasma levels during long-term treatment with Norplant subdermal implants.
    Croxatto HB; Díaz S; Pavez M; Brandeis A
    Contraception; 1988 Oct; 38(4):465-75. PubMed ID: 3145171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
    Landgren BM; Diczfalusy E
    Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
    Alvarez F; Brache V; Tejada AS; Faúndes A
    Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levonorgestrel and progesterone levels in women treated with silastic covered rods containing levonorgestrel.
    Croxatto HB; Díaz S; Brandeis A; Pavez M; Johansson ED
    Contraception; 1985 Jun; 31(6):643-54. PubMed ID: 3930143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Norplant implants: the mechanism of contraceptive action.
    Segal SJ; Alvarez-Sanchez F; Brache V; Faundes A; Vilja P; Tuohimaa P
    Fertil Steril; 1991 Aug; 56(2):273-7. PubMed ID: 1906407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
    Joshi UM; Joshi JV; Donde UM; Sankoli GM; Virkar KD; Saxena BN
    Contraception; 1985 Jan; 31(1):71-82. PubMed ID: 3921309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
    Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
    Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.
    Alvarez F; Faundes A; Johansson E; Coutinho E
    Fertil Steril; 1983 Jul; 40(1):120-3. PubMed ID: 6407876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
    Landgren BM; Johannisson E; Masironi B; Diczfalusy E
    Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
    Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and endocrinologic study of continuous levonorgestrel administration from subcutaneous solid polydimethylsiloxane rods.
    Roy S; Stanczyk F; Mishell DR; Lumkin M; Gentzschein E
    Contraception; 1980 Jun; 21(6):595-615. PubMed ID: 6775868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic changes during treatment with two different progestogens.
    Refn H; Kjaer A; Lebech AM; Borggaard B; Schierup L; Bremmelgaard A
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):374-7. PubMed ID: 2115298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels.
    Ory SJ; Hammond CB; Yancy SG; Hendren RW; Pitt CG
    Am J Obstet Gynecol; 1983 Mar; 145(5):600-5. PubMed ID: 6402933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD.
    Croxatto HB; Diaz S; Robertson DN; Pavez M
    Contraception; 1983 Mar; 27(3):281-8. PubMed ID: 6406139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.